Results 201 to 210 of about 28,931 (239)

Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function

Current Opinion in Obstetrics & Gynecology, 2007
This review addresses the effects of gonadotropin-releasing hormone agonists and antagonists on various aspects of the luteal phase.Recent studies have shown that use of both gonadotropin-releasing hormone agonists and antagonists during in-vitro fertilization cycles leads to alterations in the hormonal profiles of the luteal phase as well as changes ...
Andrea J, DiLuigi, John C, Nulsen
openaire   +2 more sources

Basic understanding of gonadotropin-releasing hormone–agonist triggering

Fertility and Sterility, 2015
A single bolus of human chorionic gonadotropin (hCG) at midcycle has been the gold standard for triggering final oocyte maturation and ovulation in assisted reproductive technology cycles. More recently, gonadotropin-releasing hormone (GnRH)-agonist (GnRH-a) triggering has been introduced.
openaire   +2 more sources

Gonadotropin releasing hormone agonists and hormone replacement theory

Reproductive Medicine Review, 1996
It has been clearly demonstrated that GnRHa is a powerful suppressant of ovarian steroidogenesis and, as a result, provides alternative strategies in dealing with certain gynaecological disorders. A concern for the deleterious effects of oestrogen deprivation is underscored by the potential long-term application of these compounds.
openaire   +1 more source

Gonadotropin-releasing hormone agonists.

Postgraduate medicine
Preview Gonadotropin-releasing hormone (GnRH) agonists will have a significant impact on the practice of medicine in the 1990s. These agents will likely be given to increasing numbers of patients, and primary care physicians themselves may wish to prescribe the drugs when appropriate.
openaire   +1 more source

Gonadotropin-Releasing Hormone Agonists in Fertility Preservation

2011
Fertility preservation in females diagnosed with cancer has become an important area of investigation due to increasing cancer survival rates combined with delayed childbearing. Initial studies using gonadotropin-releasing hormone (GnRH) agonist cotreatment with chemotherapy demonstrated promising results for fertility preservation.
Hakan Cakmak, Emre Seli
openaire   +1 more source

Gonadotropin-releasing hormone agonist in a GIFT program.

New Jersey medicine : the journal of the Medical Society of New Jersey, 1992
The authors describe their experience with the gamete intrafallopian transfer (GIFT) procedure in the treatment of infertility. Utilization of a gonadotropin-releasing hormone agonist resulted in a 51.9 percent clinical pregnancy rate and a low cancellation rate.
G H, Corsan, E, Kemmann
openaire   +1 more source

Management of endometriosis with gonadotropin-releasing hormone agonists

Fertility and Sterility, 1985
openaire   +2 more sources

Short-term use of gonadotropin-releasing hormone agonist

Journal of In Vitro Fertilization and Embryo Transfer, 1988
D, Kreiner, Z, Rosenwaks
openaire   +2 more sources

Gonadotropin-Releasing Hormone Agonists: Treatment of Endometriosis

Clinical Obstetrics and Gynecology, 1993
openaire   +2 more sources

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study

Fertility and Sterility, 2016
Lan N Vuong, Tuong M Ho, Duc T Ha
exaly